iscalimab
First-of-its-kind data shows Novartis’ iscalimab extends survival of transplanted kidneys
June 6, 2019Research and Development Novartis, iscalimab, kidney transplant, pharma, transplant
In a first-of-its-kind reveal, Novartis has presented histology data for iscalimab (CFZ533) at the American Transplant Congress (ATC) which indicates …
Latest content
The evidence bar impacting UK medical cannabis access
November 6, 2026
Addressing the rheumatic disease diagnostic gap in primary care
November 5, 2026
